Quintiles began its first global study involving Indonesia, through an exclusive alliance with Prodia Clinical Laboratory to provide in-country testing of samples from Indonesian patients in clinical trials. Indonesia has previously been difficult to include in global trials because of requirements that all local samples be tested in-country before data can be exported. The alliance with Prodia allows Quintiles to test trial samples.

“We have embarked on a new chapter for clinical research in Indonesia with the placement of our first study there using Prodia’s CAP-accredited harmonized central laboratory,” said Alan Ong, vice president and general manager of Quintiles Southeast Asia. “Indonesia is now part of a diabetes study that’s expected to enroll about 14,000 patients globally. This is testament to Quintiles’ commitment to obtain evidence of the potential benefits of new medicines in patient populations for whom they are intended.”

In November 2011, Quintiles partnered with Jakarta-based Prodia Clinical Laboratory through its sister company Prodia CRO, giving Quintiles access to Prodia’s central lab for a two-year period.

Endang Hoyaranda, president director of Prodia Group, said, “Prodia is proud to partner with Quintiles in establishing Indonesia as a regional hub for clinical trials. As the local market leader and only CAP-accredited central laboratory in Indonesia, Prodia is playing a significant role in helping establish Indonesia as a clinical trial center of excellence.”